GPE analogs and peptidominetics

Details GPE analogs and peptidominetics GPE analogs and peptidominetics

2006-05-09

2006-05-09

Saeed, Kamal A. (Department: 1626)

Drug, bio-affecting and body treating compositions

Preparations characterized by special physical form

Capsules

C548S537000, C424S464000, C514S423000

Reexamination Certificate

active

07041314

ABSTRACT:
This invention relates to analogs and peptidomimetics of glycyl-L-prolyl-L-glutamic acid (GPE). In particular, this invention relates to GPE analogs and peptidomimetics that are anti-apoptotic and anti-necrotic, to methods of making them, to pharmaceutical compositions containing them, and to their use.

REFERENCES:
patent: 4444879 (1984-04-01), Foster et al.
patent: 4511390 (1985-04-01), Kauer et al.
patent: 4699875 (1987-10-01), Appel et al.
patent: 4783524 (1988-11-01), Larsen et al.
patent: 4906614 (1990-03-01), Giertz et al.
patent: 5068224 (1991-11-01), Fryklund et al.
patent: 5089406 (1992-02-01), Williams et al.
patent: 5093317 (1992-03-01), Lewis et al.
patent: 5106832 (1992-04-01), Froesch et al.
patent: 5114840 (1992-05-01), Tryggvason et al.
patent: 5149657 (1992-09-01), Maugh et al.
patent: 5243038 (1993-09-01), Ferrari et al.
patent: 5273961 (1993-12-01), Clark et al.
patent: 5420112 (1995-05-01), Lewis et al.
patent: 5451660 (1995-09-01), Builder et al.
patent: 5496712 (1996-03-01), Cappello et al.
patent: 5635604 (1997-06-01), Dalboge et al.
patent: 5639729 (1997-06-01), Goldstein et al.
patent: 5648335 (1997-07-01), Lewis et al.
patent: 5670616 (1997-09-01), Weber
patent: 5679552 (1997-10-01), Dalboge et al.
patent: 5686423 (1997-11-01), Wang et al.
patent: 5691169 (1997-11-01), Dalboge et al.
patent: 5703045 (1997-12-01), Lewis et al.
patent: 5710252 (1998-01-01), Weber et al.
patent: 5714460 (1998-02-01), Gluckman et al.
patent: 5750376 (1998-05-01), Weiss et al.
patent: 5801045 (1998-09-01), Weber et al.
patent: 5804550 (1998-09-01), Bourguignon et al.
patent: 5804563 (1998-09-01), Still et al.
patent: 5861373 (1999-01-01), Gluckman et al.
patent: 5965531 (1999-10-01), Webster et al.
patent: 6054579 (2000-04-01), Harriman
patent: 6187906 (2001-02-01), Gluckman et al.
patent: 6294585 (2001-09-01), Brown
patent: 6342585 (2002-01-01), Grossman
patent: 6365573 (2002-04-01), Gluckman et al.
patent: 6444657 (2002-09-01), Slusher et al.
patent: 6682753 (2004-01-01), Alexi
patent: 2001/0018199 (2001-08-01), Dalboge et al.
patent: 2002/0013277 (2002-01-01), Gluckman et al.
patent: 2002/0035066 (2002-03-01), Gluckman et al.
patent: 2002/0115594 (2002-08-01), Bourguignon
patent: 2002/0151522 (2002-10-01), Alexi
patent: 2002/0177239 (2002-11-01), Guan et al.
patent: 2003/0027755 (2003-02-01), Guan et al.
patent: 2003/0105072 (2003-06-01), Degenhardt et al.
patent: 2003/0211990 (2003-11-01), Sieg et al.
patent: 227619 (1987-01-01), None
patent: 289314 (1988-02-01), None
patent: 308386 (1989-03-01), None
patent: 366638 (1990-05-01), None
patent: 357240 (1993-01-01), None
patent: 1043027 (2000-11-01), None
patent: 2707170 (1995-01-01), None
patent: WO 88/03533 (1988-05-01), None
patent: WO 88/08848 (1988-11-01), None
patent: WO 88/09171 (1988-12-01), None
patent: WO 89/01343 (1989-02-01), None
patent: WO 89/05822 (1989-06-01), None
patent: WO 90/05177 (1990-05-01), None
patent: WO 92/09695 (1992-06-01), None
patent: WO 93/02695 (1993-02-01), None
patent: WO 93/08826 (1993-05-01), None
patent: WO 93/08828 (1993-05-01), None
patent: WO 93/10806 (1993-06-01), None
patent: WO 93/20836 (1993-10-01), None
patent: WO 93/21216 (1993-10-01), None
patent: WO 94/23754 (1994-10-01), None
patent: WO 94/26301 (1994-11-01), None
patent: PCT/NZ 94/00143 (1994-12-01), None
patent: WO 95/13823 (1995-05-01), None
patent: WO 95/17204 (1995-06-01), None
patent: WO 97/17090 (1997-05-01), None
patent: WO 97/39032 (1997-10-01), None
patent: WO 97/47735 (1997-12-01), None
patent: WO 98/14202 (1998-04-01), None
patent: WO 98/52620 (1998-11-01), None
patent: WO98/52620 (1998-11-01), None
patent: WO 99/08702 (1999-02-01), None
patent: WO 99/15192 (1999-04-01), None
patent: WO 99/39210 (1999-08-01), None
patent: WO 99/65509 (1999-12-01), None
patent: WO 00/13650 (2000-03-01), None
patent: WO 02/16408 (2002-02-01), None
patent: WO 02/076208 (2002-10-01), None
patent: WO 02/94856 (2002-11-01), None
J. Neel, Pure and Applied Chemistry (1972), 31(1-2), 201-25.
Carl Axel Bauer, European Journal of Biochemistry (1980), 105(3), 565-70.
Blasio et al., Biopolymers (1993), 33 (4), 621-31.
Challis et al., Journal of the Chemical Society, Perkin Transactions 1: Organic and Bio-Organic Chemistry (1990), (11), 3103-8.
Hanusch-Kompa. et al.,Multi-Component Reactions 13: Synthesis of γ-Lactams as Part of a Multi-Ring System via Ugi-4-Centre-3-Component Reactions. Tetrahedron Letters. 39 (1998) pp. 2725-2728.
Weinstein B., “Chemistry and Biochemistry of Amino Acids, Peptides and Proteins” vol. 7, 1983, pp. 266-357, XP002032461, Chapter 5, Arno F. Spatola.
Lucas, M.D., D. R., et. al., “The Toxic Effect of SodiumL-Glutamate on the Inner Layers of the Retina”,Archives of Opthamology, 58, 1957, pp. 198-204.
Curtis, David R., et al., “Amino Acid Transmitters in the Mammalian Central Nervous System”,Ergebnisse der Physiologie, 69, 1974, pp. 97-188.
Bauer, Carl-Axel, “Active Centers of α-Chymotrypsin and ofStreptomyces griseusProteases 1 and 3,” Department of Biochemistry, University of Lund, Nov. 5, 1979, pp. 565-570.
Carone, R.A. et al., “Differences Betweenin vitroandin vivoDegradation of LHRH by Rat Brain and Other Organs,”American Journal of Physiology, 253, 1987, E317-E321.
Szabo, Laszlo, et. al., “The Bovine Insulin-like Growth Factor (IGF) Binding Protein Purified from Conditioned Medium Requires the N-Terminal Tripeptide in IGF-1 for Binding,”Biochemical and Biophysical Research Communications, vol. 151, No. 1, Feb. 29, 1988, pp. 207-214.
Shepard, M.D., Gordon M., “Neurotransmitters and Neuromodulators,”Neurobiology, 2ndedition, 1988, pp. 145-176.
Sakaki, Atsushi, et al., “Multiple Forms of Immunoreactive Growth Hormone-Releasing Hormone in Human Plasma, Hypothalamus, and Tumor Tissues,”Journal of Clinical Endocrinology and Metabolism, vol. 68, No. 1, 1989, pp. 180-185.
Bourguignon, Jean-Pierre, et. al., “Pulsatile Release of Gonadortropin-Releasing Hormone from Hypothalamic Explants is Restrained by Blockade of N-Methyl-D,L-Aspartate Receptors,”Endocrinology, vol. 125, No. 2, 1989, pp. 1090-1096.
Sara, Vicki R., et. al., “Identification of Gly-Pro-Glu (GPE), the Aminoterminal Tripeptide of Insulin-like Growth Factor 1 Which is Truncated in Brain, as a Novel Neuroactive Peptide,”Biochemical and Biophysical Research Communications, vol. 165, No. 2, Dec. 15, 1989, pp. 766-771.
Donoso, Alfredo O., et. al., “Glutamate Receptors of the Non-N-Methyl-D-Aspartic Acid Type Mediate the Increase in Luteinizing Hormone-Releasing Hormone Release by Excitatory Amino Acidsin Vitro”, Endocrinology, vol. 126, No. 1, 1990, pp. 414-420.
Bourguignon, Jean-Pierre, et. al., “Maturation of the Hypothalamic Control of Pulsatile Gonadotropin-Releasing Hormone Secretion at Onset of Puberty: II. Reduced Potency of an Inhibitory Autofeedback,”Endocrinology, vol. 127, No. 6, 1990, pp. 2884-2890.
Challis, Brian C., et al., “Synthesis and Characterisation of Some New N-Nitrosodipeptides,” J. Chemistry Society Perkin Trans., 1990, pp. 3103-3108.
Sara, Vicki R., et al., “Neuroactive Products of IGF-1 and IGF-2 Gene Expression in the CNS,”Molecular Biology and Physiology of Insulin and Insulin-Like Growth Factors, New York, 1991, pp. 439-448.
Hiney, Jill K., et al., “Insulin-Like Growth Factor I: A Possible Metabolic Signal Involved in the Regulation of Female Puberty,”Neuroendocrinology, 54, 1991, pp. 420-423.
Bourguignon, Jean-Pierre, et. al., “Gonadal-Independent Developmental Changes in Activation of N-Methyl-D-Aspartate Receptors Involved in Gonadotropin-Releasing Hormone Secretion,”Neuroendocrinology, 55, 1992, pp. 634-641.
Guan, Jian, et. al., “The Effects of IGF-1 Treatment After Hypoxic-Ischemic Brain Injury in Adult Rats,”J Cereb Blood Flow Metab, vol. 13, No. 4, 1993, pp. 609-616.
Nilsson-Hakansson, Lena, et al., “The Effects of 1GF-1, Truncated IGF-1 and the Tripeptide Gly-Pro-Glu on

Affiliated with

Also associated with

Rating

GPE analogs and peptidominetics does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with GPE analogs and peptidominetics, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and GPE analogs and peptidominetics will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3561710